Zydus Anemia Drug Desidustat Secures Key Approval in China

Zydus Lifesciences Gains China Market Access

Zydus Lifesciences announced on March 13, 2026, that its innovative drug, Desidustat, has received marketing approval from China's National Medical Products Administration (NMPA). The oral tablets are intended for treating anemia in adult patients with Chronic Kidney Disease (CKD) who are not on dialysis. This regulatory clearance marks a significant step for the Indian pharmaceutical company, opening up access to one of the world's largest healthcare markets. The approval was secured through its partner, China Medical System Holdings Limited (CMS), which holds the exclusive rights to commercialize the drug in Greater China.

A Strategic Partnership for a Major Market

The foundation for this approval was laid on January 20, 2020, when Zydus Lifesciences granted an exclusive, royalty-bearing license to CMS International Development and Management Limited, a wholly-owned subsidiary of CMS. The agreement covers the development, registration, manufacturing, and commercialization of Desidustat in Greater China, which includes Mainland China, Hong Kong, Macao, and Taiwan. This collaboration leverages Zydus's drug discovery capabilities with CMS's expertise in clinical development and market access within China, accelerating the drug's journey to patients in the region.

Understanding Desidustat and Its Mechanism

Desidustat is a novel, first-in-class oral medication belonging to the Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) category. Its mechanism of action is designed to mimic the body's natural response to low oxygen levels. By inhibiting the HIF-PH enzyme, Desidustat promotes the production of endogenous erythropoietin, a hormone that stimulates the creation of red blood cells. Additionally, it improves the body's ability to use iron by reducing hepcidin levels, thereby addressing the root causes of anemia in CKD patients. As an oral tablet, it offers a more convenient treatment option compared to injectable alternatives, potentially improving patient compliance.

Positive Phase III Trial Results in China

The NMPA's approval was supported by robust data from a Phase III clinical trial conducted in China. The study demonstrated that Desidustat was significantly more effective than a placebo in raising hemoglobin (Hb) levels in non-dialysis CKD patients. The trial successfully met its primary endpoint, which measured the mean change in Hb levels from the baseline to weeks 7-9. The results showed a clear therapeutic benefit and an acceptable safety profile, paving the way for regulatory clearance.

Addressing a Significant Unmet Need

The market potential for Desidustat in China is substantial. It is estimated that over 120 million people in the country live with Chronic Kidney Disease, a condition that often leads to severe anemia. Anemia in CKD patients contributes to fatigue, reduced quality of life, and increased cardiovascular risks. The availability of a new oral treatment like Desidustat provides a crucial alternative for managing this common complication, addressing a large and persistent unmet medical need.

Proven Success in the Indian Market

Before its entry into China, Desidustat was discovered, developed, and launched by Zydus in India under the brand name Oxemia. Since its launch in 2022, the drug has established a strong track record, having been used to successfully treat more than 100,000 CKD patients across India. This real-world evidence of its efficacy and safety in a large patient population likely provided additional confidence for its development and registration in other markets.

Management's Perspective on the Milestone

Sharvil P Patel, Managing Director of Zydus Lifesciences, commented on the approval, stating, "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally." This statement underscores the company's focus on innovation and its strategic goal of expanding the reach of its novel therapies to international markets.

What This Approval Means for Zydus

The approval of Desidustat in China is a major commercial and strategic victory for Zydus Lifesciences. It validates the company's research and development capabilities and represents a key step in its global expansion strategy. The partnership with CMS is expected to ensure a strong commercial launch and penetration into the vast Chinese market, potentially generating significant royalty revenues for Zydus in the coming years. This milestone strengthens Zydus's position as a global pharmaceutical player with a portfolio of innovative, self-developed products.